Guanhao Biotech Co., Ltd. Class A

Guanhao Biotech Co., Ltd. Class A

SSZSE:300238
9.91
CNY
-0.27
(-2.65%)
0.00EPS
231.03P/E
3.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.69
0.76
0.93
1.26
1.72
1.7
1.65
1.69
1.86
1.42
1.56
1.38
1.43
1.31
Basic EPS, GAAP
0.16
0.2
0.26
0.23
0.17
0.17
-1.75
0.18
0.28
-1.16
0.12
0.1
0.09
0.05
Free Cash Flow per Basic Share
- -
0.14
0.2
-0.14
-0.26
-0.01
0.32
0.39
0.45
0.11
- -
-0.1
0.12
- -
Dividend per Share
0.05
0.05
0.05
0.03
0.09
0.11
0.06
0.05
0.03
0.01
- -
0.01
0.01
0.01
Book Value per Share
1.96
2.15
2.35
5.25
4.4
4.35
2.68
2.75
2.96
1.83
1.96
2.05
2.15
2.48
Tangible Book Value per Share
1.73
1.87
1.98
2.7
1.82
1.72
1.54
1.65
1.88
1.44
1.59
1.67
1.76
2.11
Basic Weighted Avg Shares
246
251
244
248
268
269
266
259
263
265
258
274
271
262
Sales/Revenue/Turnover
169
190
226
313
461
458
438
437
489
377
404
377
388
345
Operating Margin (%)
19.72
23.76
26.91
18.98
14.83
13.99
-9.42
15.63
21.03
13.05
13.66
14.17
9.06
4.72
Depreciation Expense
16
18
22
25
27
26
31
28
39
33
29
27
26
- -
Net Income, GAAP
41
50
63
57
46
46
-465
47
74
-308
31
27
24
14
Effective Tax Rate (%)
12.5
15.78
15.81
21.19
33.73
32.56
- -
7.83
38.17
- -
34.33
40.73
45.8
89.01
Profit Margin (%)
24.08
26.32
28.02
18.21
9.88
9.98
-106.27
10.66
15.07
-81.59
7.67
7.26
6.28
3.94
Working Capital
265
255
253
322
200
146
144
125
173
110
95
88
137
251
LT Debt
- -
- -
- -
- -
160
150
105
94
36
23
24
83
106
114
Total Equity
483
532
621
1,457
1,212
1,154
704
717
748
431
456
468
488
590
Return on Invested Capital (%)
7.13
8.42
8.23
2.93
2.01
1.94
- -
4.29
5.42
- -
4.54
3.27
2.95
- -
Return on Capital (%)
7.53
8.72
10.39
6.3
4.12
4.8
- -
6.71
10.8
- -
8.25
7.15
6.06
- -
Return on Common Equity (%)
8.66
9.87
11.39
5.77
3.56
3.95
-49.93
6.46
9.73
-48.5
6.16
5.16
4.38
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
21
20
10
LT Borrowings
113
114
114
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
275
Market Capitalization
3,839
3,076
3,283

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
308
297
380
Cash, Cash Equivalents & STI
144
146
223
Accounts Receivable, Net
61
52
52
Inventories
71
66
62
Total Current Liabilities
154
145
129
Payables & Accruals
- -
- -
- -
ST Debt
21
20
10
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.07%
-5.06%
4.33%
Free Cash Flow
-1,854.17%
-2,402.25%
-224.98%
Net Income, GAAP
-184.94%
-118.49%
-11.2%
Sales/Revenue/Turnover
7.27%
-1.54%
2.72%
Total Cash Common Dividend
16.5%
-2.38%
48.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
98
88
99
377
2025
95
106
- -
94
388
2026
93
81
76
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.02
0.03
- -
0.1
2025
0.06
0.02
- -
-0.01
0.09
2026
0.04
0.01
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Feng Zhao
Full Time Employees
535
Sector
Health technology
Industry
Medical specialties
Address
No. 12 Yuyan Road Guangzhou GD China 510530
IPO Date
Jun 24, 2011
Business
Guanhao Biotech Co., Ltd. engages in the research, development, production, and sale of regenerative medical materials and implantable medical devices. The company's core product offerings include biological dura mater repair patches such as NormalGEN and GrandNeuro for neurosurgery; surgical patches like ThormalGEN; wound dressing products including DermalGEN for burns and trauma wounds; and specialized products such as IREAL breast patches and Youvision corneal grafts. Additionally, Guanhao produces sterile biological wound membranes, thoracic surgery repair patches, biological dura mater spine patches (Type B dura), artificial lenses, and medical instruments. It also provides advanced cell technology services. These products and services primarily serve medical fields including neurosurgery, thoracic surgery, ophthalmology, dermatology, orthopedics, and cosmetology. Founded in 1999 and headquartered in Guangzhou, China, Guanhao Biotech primarily operates within the domestic Chinese market. In recent developments, the company continues to expand its regenerative medicine portfolio and life sciences business model, integrating biomaterials, stem cells, pharmaceuticals, and advanced medical technologies into a “3+1” framework encompassing materials, cells, pharmaceuticals, and a technology incubation platform. Recent strategic moves include enhanced focus on innovative drug development, participation in commercial insurance programs for innovative drugs, and international cooperation efforts to promote high-quality pharmaceutical advancements. The company maintains a strong emphasis on expanding its technological platform and product pipeline in the regenerative medicine sector while strengthening its position within China’s medical device marketplace. Guanhao’s recent product innovation and business expansion efforts align with industry trends toward advanced regenerative medicine and innovative pharmaceutical technologies, supporting growth through strategic partnerships and capital market engagement. This includes ongoing R&D in small molecule drugs, prophylactic and mRNA vaccines, and clinical trial activities. Guanhao Biotech targets patients requiring surgical repair of tissue and organ damage and healthcare institutions across China. The company employs over 500 personnel and positions itself as a key player in regenerative medical device manufacturing with a growing footprint in biotech innovation and cell technology services.